| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| 100mg | |||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
Lvguidingan targets the serotonergic system in the brain. It increases the concentration of serotonin (5-HT) and its metabolite 5-hydroxyindoleacetic acid (5-HIAA). This elevation in neurotransmitter levels enhances neuronal inhibition and reduces the likelihood of seizure occurrence. The compound's mechanism of action is related to modulation of serotonin signaling.
|
|---|---|
| ln Vitro |
In vitro, lvguidingan has been found to possess a wide range of biological activities, including anti-inflammatory, antioxidant, antitumor, and antiviral properties. Detailed in vitro activity data is limited in publicly available sources.
|
| ln Vivo |
In vivo, lvguidingan increases the concentration of serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) in the mouse brain. It has anticonvulsant/antiepileptic effects. The compound also has sedative-hypnotic, sedative, and muscle relaxing effects. It is used as an anti-epileptic agent.
|
| Enzyme Assay |
Non-cellular assays for lvguidingan are not typically performed as it is not an enzyme inhibitor. The compound's identity and purity are confirmed by standard analytical methods such as NMR and HPLC.
|
| Cell Assay |
In vitro cellular experiments involve treating neuronal cells with lvguidingan to assess its effects on serotonin levels and neuronal activity. Neurotransmitter levels and neuronal firing rates are measured. Specific protocols are described in the primary literature.
|
| Animal Protocol |
In vivo animal studies involve administration of lvguidingan to rodents. Brain levels of serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) are measured. Anticonvulsant efficacy is assessed in seizure models. Sedative and muscle relaxing effects are also evaluated.
|
| ADME/Pharmacokinetics |
Lvguidingan has a molecular weight of 272.17 g/mol and a molecular formula of C₁₃H₁₅Cl₂NO. It is also known as Anticonvulsant 7903 and 3,4-dichlorophenyl propenylisobutylamide. The compound is soluble in DMSO.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for lvguidingan is limited. As an anticonvulsant/antiepileptic agent, it is expected to have on-target effects related to serotonin modulation. The compound is for research purposes only and should be handled with appropriate safety precautions.
|
| References |
Patejdl R, Leroux AC, Noack T. Phenytoin inhibits contractions of rat gastrointestinal and portal vein smooth muscle by inhibiting calcium entry. Neurogastroenterol Motil. 2015 Oct;27(10):1453-65.
|
| Additional Infomation |
Lvguidingan (Anticonvulsant 7903, 3,4-dichlorophenyl propenylisobutylamide) is an anticonvulsant/antiepileptic agent that increases serotonin and 5-HIAA levels in the brain. It also has sedative-hypnotic, muscle relaxing, and anti-inflammatory effects. This product is for research purposes only and is not for human therapeutic use.
|
| Molecular Formula |
C13H15CL2NO
|
|---|---|
| Molecular Weight |
272.170301675797
|
| Exact Mass |
271.053
|
| CAS # |
82351-05-1
|
| Related CAS # |
82351-05-1
|
| PubChem CID |
5736735
|
| Appearance |
White to off-white solid powder
|
| LogP |
4
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
17
|
| Complexity |
281
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCC(C)NC(=O)/C=C/C1=CC(=C(C=C1)Cl)Cl
|
| InChi Key |
WMHSFCNWWYFBSS-FNORWQNLSA-N
|
| InChi Code |
InChI=1S/C13H15Cl2NO/c1-3-9(2)16-13(17)7-5-10-4-6-11(14)12(15)8-10/h4-9H,3H2,1-2H3,(H,16,17)/b7-5+
|
| Chemical Name |
(E)-N-butan-2-yl-3-(3,4-dichlorophenyl)prop-2-enamide
|
| Synonyms |
Anticonvulsant 7903 Lvguidingan Chlocibutamine.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~459.27 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.08 mg/mL (7.64 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.64 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6742 mL | 18.3709 mL | 36.7417 mL | |
| 5 mM | 0.7348 mL | 3.6742 mL | 7.3483 mL | |
| 10 mM | 0.3674 mL | 1.8371 mL | 3.6742 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
